Eikon Therapeutics

Eikon Therapeutics, based in Millbrae, California, the United States, is a biotechnology company. A drug discovery company that also has offices in New York and Jersey City and lists clinical-stage oncology, immunology and neuroscience programmes on its pipeline page, including TLR7/8, PARP1, PARP1-CNS penetrant, AR, VCP and AR-v7 targeted programmes. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing EIK1001, EIK1004-001 (IMP1707-001), IMP1734 and EIK1005 in melanoma, non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, colorectal cancer and endometrial cancer. The largest, NCT07365319 (A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer), plans to enrol 750 participants. Eikon went public on the Nasdaq Global Select Market in February 2026, selling 21,177,600 shares at USD 18.00 in its initial public offering under the symbol EIKN. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website and the IPO prospectus.